Concord Holdings (The company or CCM) was listed on the New York Stock Exchange (NYSE : CCM) in 2009. The Company has been deeply engaged in the field of cancer imaging diagnosis and radiotherapy services for a long time, and are committed to providing patients with high quality, international, patient-centered multidisciplinary diagnosis and treatment services.
CCM was founded in 1997, contain three main business: 1) multi-disciplinary diagnosis and treatment premium cancer hospitals featuring proton therapy and an international hospital : Beijing Proton Medical Center, Guangzhou Concord Cancer Center, Shanghai Concord Cancer Center, Singapore Concord International Hospital; 2) Level II Cancer hospitals and independent medical institutions: Datong Meizhong Jiahe Cancer Center, Wuxi Meizhong Jiahe Cancer Center, Shanghai Meizhong Jiahe Cancer Center, Shanghai Meizhong Jiahe Medical Imaging Diagnosis Center; 3) Image Diagnosis and Radiotherapy Cooperation Centers.
The company has signed 10 years cooperation agreement and a proton training cooperation agreement with MD Anderson Cancer Center to build and operate MD Anderson brand cancer hospitals in China and Asia. The Premium Cancer Centers in Guangzhou and Shanghai have been approved as level III hospitals, which are under construction. Singapore Concord International Hospital provides the most advanced international cancer diagnosis and treatment services for patients in the Middle East and Southeast Asia. Concord Medical Hospital Management Group – a subsidiary company of CCM, who obtained strategic investment from large state-owned financial institutions such as CICC Capital and other financial institutions in March 2018.